1[1]Press OW, Rasey J. Principles of radioimmunotherapy for hematologists and oncologists. Semin Oncol. 2000,27:62
2[2]Press OW, Shan D, Howell-Clark J et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res, 1996,56:2123
3[3]DeNardo GL, Kukis DL, Shen S et al. 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkins lymphoma. Clin Cancer Res,1999,5:533
4[4]Tedder TF, Engel P. CD20: A regulator of cell-cycle progression of B lymphocytes. Immunol Today, 1994,15:450
5[5]Vervoordeldonk SF, Heikens J, Goedemans WT et al. 99mTc-CD19 monoclonal antibody is not useful for imaging of B cell non- Hodgkin's lymphoma. Cancer Immunol Immunother, 1996,42:291
6[6]Lobuglio AF, Saleh MN. Monoclonal antibody therapy of cancer. Crit Rev Oncol Hematol, 1992,13:271
7[7]DeNardo GL, DeNardo SJ, Lamborn KR et al. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-LYM-1 antibody.Cancer Biother Radiopharm, 1998,13:239
8[8]Oliver W, Press. Radiolabeled antibody therapy of B-cell lymphomas. Seminars in Oncology, 1999(suppl 14),26:58
9[9]Witzig TE, White CA, WisemanGAetal. PhaseⅠ/Ⅱ trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma. J Clin Oncol, 1999,17:3793
10[10]Gordon L, White C, Witzig T et al. Zevalin (IDEC-Y2B8) radioimmunotherapy of Rituximab refractory follicular non-Hodgkin' s lymphoma (NHL) : Interim results. Blood, 1999(suppl 1),94: 91a
同被引文献6
1Ishii Y,Tomita N,Takasaki H,et al. Clinical features of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue [J]. Hematol Oncol, 2012,30(4) : 186-189.
2De Cicco L, Celia L, Liuzzi R, et al. Radiation therapy in primary orbital lymphoma: A single institution retrospective analysis [J]. Radiat Oncol, 2009(4) : 60.
3Goda JS, Gospodarowicz M, Pintilie M, et al. Long-term outcome in localized extranodal mucosaassociated lymphoid tissue lymphomas treated with radiotherapy[J]. Cancer,2010,116(16) 3815-3824.
4Coda JS, Le LW, Lapperriere NJ, et al. Localized orbital mucosaasso- ciated lymphoma tissue lymphoma managed with primary radiation therapy:Efficacy and toxicity[J]. Int J Radiat Oncol Biol Phys,2011, 81 (4) : e659-e666.
5Son SH, Choi BO, Kim GW, et al. Primary radiation therapy in patients with localized orbital marginal zone B-cell lyrnphoma of mu- cosa-associated lymphoid tissue (MALT lymphoma) [J]. Int J Radiat Oncol Biol Phys,2010,77(1) :86-91.
6Savino G,Battendieri R, Balia L, et al. Evaluation of intraorbital in- jection of rituximab for treatment of primary ocular adnexal lympho- ma: A pilot study[J]. Cancer Sci,2011,102(8) 1565-1567.
